ArticlemBio2018
Multisystem Analysis of
Open access · goldAbstract read
In one paragraph
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 66 citations in OpenAlex.
- Serine/threonine protein kinase phosphorylation of DosR alters target gene transcription mechanics and regulates Mycobacterium tuberculosis response to nitric oxide stress.PLoS genetics · 2026Article
- Multiple input-multiple output (MIMO) designs in two-component signalling systems of Mycobacterium tuberculosis.FEMS microbiology reviews · 2026Review
- The role of colony morphotype in shaping gene essentiality inProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Structural modeling and characterization of the Mycobacterium tuberculosis MmpL3 C-terminal domain.FEBS letters · 2024Article
- Phosphorylation of VapB antitoxins affects intermolecular interactions to regulate VapC toxin activity inJournal of bacteriology · 2024Article
- Nitric oxide induces the distinct invisibility phenotype of Mycobacterium tuberculosis.Communications biology · 2024Article
- Experimental measurement and computational prediction of bacterial Hanks-type Ser/Thr signaling system regulatory targets.Molecular microbiology · 2024Review
- Phosphorylation of VapB antitoxins affects intermolecular interactions to regulate VapC toxin activity inbioRxiv : the preprint server for biology · 2024Article
- Review
- Regulatory Intersection of Two-component System and Ser/Thr Protein Kinase Signaling in Mycobacterium tuberculosis.Journal of molecular biology · 2024Article
- Article
- MtrA modulates Mycobacterium tuberculosis cell division in host microenvironments to mediate intrinsic resistance and drug tolerance.Cell reports · 2023Article
- Molecular Mechanisms of MmpL3 Function and Inhibition.Microbial drug resistance (Larchmont, N.Y.) · 2023Review
- The Mycobacterium tuberculosis protein O-phosphorylation landscape.Nature microbiology · 2023Article
- PrrA modulates Mycobacterium tuberculosis response to multiple environmental cues and is critically regulated by serine/threonine protein kinases.PLoS genetics · 2022Article
- Mycobacterial serine/threonine phosphatase PstP is phosphoregulated and localized to mediate control of cell wall metabolism.Molecular microbiology · 2022Article
- Functional analysis of theiScience · 2022Article
- Mycobacterium tuberculosis PknK Substrate Profiling Reveals Essential Transcription Terminator Protein Rho and Two-Component Response Regulators PrrA and MtrA as Novel Targets for Phosphorylation.Microbiology spectrum · 2022Article
- PASTA kinase-dependent control of peptidoglycan synthesis via ReoM is required for cell wall stress responses, cytosolic survival, and virulence in Listeria monocytogenes.PLoS pathogens · 2021Article
- Transporters Involved in the Biogenesis and Functionalization of the Mycobacterial Cell Envelope.Chemical reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 1 country.
Xavier Carette *Division of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-4490-5752
John Platig *Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
David C YoungDivision of Rheumatology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Michaela HelmelDepartment of Pathology, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Albert T YoungDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Zhe WangDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Lakshmi-Prasad PotluriDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Cameron Stuver MoodyVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
Jumei ZengDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Sladjana PrisicDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Joseph N PaulsonDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Jan MuntelDepartment of Pathology, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Ashoka V R MadduriDivision of Rheumatology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Jorge VelardeDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Jacob A MayfieldDivision of Rheumatology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Christopher LocherVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
Tiansheng WangVertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
John QuackenbushDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kyu Y RheeDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
D Branch MoodyDivision of Rheumatology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Hanno SteenDepartment of Pathology, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Robert N HussonDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA robert.husson@childrens.harvard.edu.
Boston Children's Hospital · USBrigham and Women's Hospital · USHarvard University · USVertex Pharmaceuticals (United States) · USCornell University · USDana-Farber Cancer Institute · US
Funding
SYNAPTIC MECHANISMS IN HIPPOCAMPAL EPILEPTOGENESISP30HD018655 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI POMEROY, SCOTT LOREN · 1985 to 2015
$26.2MMetabolomics Core U19AI111224 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MOODY, DAVID BRANCH, MURRAY, MEGAN B · 2015 to 2021
$20.4MSYSTEMS APPROACHES TO THE EPIDEMIOLOGY, GENETICS AND GENOMICS OF LUNG DISEASEST32HL007427 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DAWN L DEMEO, Edwin K Silverman · 1985 to 2026
$13.6MChemical Inhibitors to Define an Essential M. Tuberculosis Signaling NetworkR01AI099204 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HUSSON, ROBERT N · 2012 to 2016
$6.1MRole of Tuberculosinyl Metabolites in M. Tuberculosis VirulenceR01AI116604 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MOODY, DAVID BRANCH · 2015 to 2019
$2.4MNHLBI NIH HHS T32 HL007427NIAID NIH HHS R01 AI099204NIAID NIH HHS R01 AI116604NIAID NIH HHS U19 AI111224NICHD NIH HHS P30 HD018655
Abstract
Tuberculosis is the leading killer among infectious diseases worldwide. Increasing multidrug resistance has prompted new approaches for tuberculosis drug development, including targeted inhibition of virulence determinants and of signaling cascades that control many downstream pathways. We used a multisystem approach to determine the effects of a potent small-molecule inhibitor of the essential
Indexed as
Adenosine TriphosphateBacterial ProteinsGene Expression Regulation, BacterialMycobacterium tuberculosisPhosphorylationProtein Serine-Threonine KinasesSignal TransductionAdenosine TriphosphateBacterial ProteinsProtein Serine-Threonine KinasesMycobacterium tuberculosisPknBSer/Thr protein kinasesignal transductiontwo-component regulatory systems
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.